Graham Ellis

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W. le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017 · 813 citations

Obesity, Metabolic Syndrome, Nutrition +8

Primary hyperparathyroidism in a paediatric hospital

Margaret L. Lawson, Steven F. Miller, Graham Ellis et al. · QJM · 1996 · 91 citations · Full text

Sporadic Phpt, Urology, Parathyroid Hormone +8

Efficacy and Safety of Insulin Glulisine in Patients with Type 1 Diabetes

M. Dreyer, Rudolf Prager, Ann Robinson et al. · Hormone and Metabolic Research · 2005 · 75 citations

A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study of the Calcium-Sensing Receptor Antagonist MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis

Johan Halse, Susan L. Greenspan, Felicia Cosman et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 42 citations · Full text